Skip to main content
Guhan Pharmaceutical Group Co., Ltd. logo

Guhan Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000590 ISIN · CNE000000701 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,714 across all filing types
Latest filing 2022-11-22 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000590

About Guhan Pharmaceutical Group Co., Ltd.

https://www.tuspharma.cn

Guhan Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sale of traditional Chinese medicine (TCM) and health-related products. The company is widely recognized for its flagship product, Guhan Yangsheng Jing, which is formulated based on ancient health preservation prescriptions discovered in the Mawangdui Han Dynasty Tombs. Its product portfolio includes oral liquids, tablets, and capsules designed to enhance vitality, support kidney function, and promote overall longevity. The organization integrates classical medical theories with modern pharmaceutical manufacturing processes to ensure product efficacy and safety. Beyond its core TCM offerings, the group engages in the production of chemical drugs and health supplements, targeting markets seeking natural wellness solutions. The company emphasizes the preservation of cultural heritage through the modernization of ancient medical wisdom.

Recent filings

Filing Released Lang Actions
第九届监事会临时会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a resolution announcement from the supervisory board of a company regarding approval of a loan application using subsidiary shares as collateral. It includes voting results and meeting details but does not contain financial statements or detailed financial data. The document is short (515 characters) and is an announcement of a board decision related to financing but not a full financing update report. It fits best under Capital/Financing Update (CAP) as it concerns financing activities and loan approval.
2022-11-22 Chinese
第九届董事会临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from the company's ninth board meeting held on November 22, 2022. It details the approval of a financing proposal involving pledging subsidiary shares for a loan. The text includes voting results and references a related financing announcement published elsewhere. The document is short (582 characters) and focuses on board decisions rather than full financial data or detailed reports. It is not an annual or interim report, nor a full audit or earnings release. It is not a regulatory filing or certification letter. The content fits best under Board/Management Information (MANG) as it announces a board meeting resolution and decision on financing matters.
2022-11-22 Chinese
关于以全资子公司股权质押申请并购贷款的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 启迪药业集团股份公司 regarding the application for a merger and acquisition (M&A) loan secured by the pledge of 100% equity of its wholly-owned subsidiary. It details the board meeting resolutions, the loan amount, terms, and the purpose of the loan related to the acquisition of Guangdong Xiantong Pharmaceutical Co., Ltd. The document does not contain financial statements or detailed financial analysis but rather focuses on the financing arrangement for an M&A transaction. Therefore, it fits the category of Capital/Financing Update (CAP) rather than a full M&A filing or financial report.
2022-11-22 Chinese
关于公司股东国有股权无偿划转暨股东权益变动的提示性公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding a change in shareholder equity due to a transfer of state-owned shares without compensation. It details the parties involved, shareholding percentages before and after the transfer, and confirms that the controlling shareholder and actual controller status remain unchanged. The document is titled as a "提示性公告" (informative announcement) and does not contain financial statements or detailed financial performance data. It is primarily an announcement of a shareholder equity change event, not a full financial report or regulatory filing. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2022-11-18 Chinese
简式权益变动报告书-股份减少（衡阳市国资委）
Major Shareholding Notification Classification · 95% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the change in shareholding structure involving the transfer of shares from the Hengyang Municipal State-owned Assets Supervision and Administration Commission to its wholly-owned subsidiary, Hongxiang Group. The document includes detailed information about the shareholding percentages before and after the transfer, the nature of the share transfer (state-owned shares transferred without compensation), approvals obtained, and declarations about the absence of restrictions or liabilities. It is a formal disclosure of a change in significant share ownership but does not report financial results, earnings, or management commentary. It is not an announcement of a report publication but the report itself. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. The document length (6103 characters) and detailed content support this classification with high confidence.
2022-11-18 Chinese
简式权益变动报告书-股份增加（衡阳弘湘集团）
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the change in shareholding of a significant shareholder (衡阳弘湘国有投资（控股）集团有限公司) in the listed company 启迪药业集团股份公司. The document includes information about the nature of the shareholding change (无偿划转 - gratuitous transfer), the parties involved, share quantities, percentages, approvals, and declarations of no other share transactions in the past 6 months. It is a formal disclosure of a change in major shareholding stakes, consistent with notifications required when a shareholder crosses significant ownership thresholds or transfers shares. There is no indication of it being a full annual or interim report, audit report, earnings release, or other types of filings. The document is not a mere announcement of a report but a detailed report on shareholding changes. Therefore, the most appropriate classification is Major Shareholding Notification (MRQ). The document length (7462 characters) supports it being a full report rather than a brief announcement.
2022-11-18 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.